Clinical Trial

Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT

Study acronym: GALILEE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Lobular Breast cancer staging with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) is not optimal due to the poor accumulation of 18F-FDG in the tumour. Through better sensitivity (and specificity), 68Ga-FAPI-46-46 PET should provide a more accurate staging of lobular breast cancer than 18F-FDG PET.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2023-06-27; most recent amendment 2026-07-03.
Status change: Recruiting → Active, Not Recruiting 2025-09-19
Status change: Not Yet Recruiting → Recruiting 2023-10-23
Trial Details
NCT Number NCT05931302
Lead Sponsor Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Collaborators: Institut Curie, Centre Antoine Lacassagne
Conditions Lobular Breast Carcinoma
Enrollment 40 participants
Start Date 2023-11-16
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-07